The main objective of the present work was to develop extended release matrix tablets of ranolazine, to reduce the frequency of administration and to improve the patient compliance; a once daily extended release formulation of ranolazine is desirable. Ranolazine is an anti-anginal drug used to treat chronic stable angina in adults. The main drawback with normal conventional dosage form is that the solubility of ranolazine is relatively high at the lower pH (4.5 and below) and also has short plasma half-life of 7 hrs. Ranolazine comes under class II of biopharmaceutical classification system. The ranolazine 500 mg extended release matrix tablets were prepared by wet granulation method using different polymers. Pre-formulation studies were done initially and the results were found to be within the limits. All the mentioned batches were prepared and granules were evaluated for pre-compression parameters such as loss on drying, bulk density, tapped density, hasuner’s ratio and compressibility index. Tablets were evaluated for weight variation, thickness, hardness and friability, were found to be within limits. The in-vitro release of ranolazine extended release tablets was studied in 900 ml of 0.1 N HCl as dissolution medium using a USP dissolution paddle assembly at 50 rpm and 37±0.5°C for 24 hrs. Final selection of formulation (F8) exhibited in-vitro drug release that matched with marketed product (Rancad 500 mg). The (F8) formulation shown best results of 99.26% drug release in 24 hrs.
Loading....